On January 7, 2022, the Board of Directors of PTC Therapeutics, Inc. promoted Matthew Klein, the Company's Chief Development Officer, to the role of Chief Operating Officer, effective immediately. Dr. Klein, 50, has been the Company's Chief Development Officer since April 2020. Dr. Klein joined the Company in October 2019 as Global Head Gene and Mitochondrial Therapies and became Global Head Clinical Development in March 2020.

Prior to joining the Company, Dr. Klein was Chief Executive Officer of BioElectron Technology Corporation from 2018 to 2019, and served as a board member of BioElectron from 2018 to 2020.